Case Study 1: The Whistleblower's Dilemma

Background

Priya Raghavan is a senior quality assurance analyst at Meridian Pharmaceutical Distributors, a mid-sized company that supplies generic medications to hospitals and pharmacies across several states. She has worked there for six years. She is well-regarded, recently promoted, and in the middle of a three-year vesting schedule on her stock options.

Over the past four months, Priya has noticed a pattern of irregularities in temperature-monitoring logs for a class of insulin products that require strict cold-chain storage. The logs show consistent storage within specification — but she has reason to believe the logs are being manually adjusted. The actual storage temperatures on two occasions exceeded safe limits by enough to potentially compromise product efficacy.

Priya is not a pharmacologist. She cannot say definitively that the products were harmed. She can say that the company appears to be falsifying compliance records. If the insulin has been compromised and this reaches patients with type 1 diabetes, the consequences could include serious harm or death.

What Priya Knows and Doesn't Know

Priya knows: - She has seen strong evidence of falsified temperature logs - Two documented temperature excursions above safe storage thresholds - Her direct supervisor, when she raised the issue informally, responded: "I wouldn't go digging around in that data if I were you" - The company's compliance officer is a close friend of the CEO

Priya doesn't know: - Whether the products were actually compromised at the molecular level - Whether this is a systemic company practice or a department-level cover-up - Whether patients have been harmed - Whether any regulatory agency is already investigating

The Options

Option 1: Do nothing Priya concludes she's probably misread the situation, or that someone else will catch it, or that the risk to her career and stock options isn't worth it. She continues in her role.

Option 2: Raise it internally through formal channels Priya submits a formal written concern to the compliance department, creating a paper trail. This is within policy and gives the company the opportunity to self-correct.

Option 3: Go to her industry's regulatory body Priya reports her concerns to the FDA's MedWatch program or her state's board of pharmacy. This is legal and protected under federal whistleblower statutes — but will almost certainly become known to her employer.

Option 4: Go public Priya contacts a journalist. She reasons that internal and regulatory channels may both be captured or slow, and that public pressure is the most likely way to force actual change.

Applying the Frameworks

DeGeorge's Criteria

Work through DeGeorge's whistleblowing framework for each option:

  1. Seriousness of harm: How do you assess the severity of the potential harm here? Does uncertainty about whether harm has occurred affect the moral analysis?

  2. Clarity of wrongdoing: The log falsification is itself a serious violation even if the products were not compromised. Does that change anything?

  3. Internal channels: Priya raised it informally and received a veiled warning. Does this satisfy "exhausting internal channels," or is the formal compliance submission still required?

  4. Evidence: What does Priya actually have? Is documentation of temperature excursions and log discrepancies sufficient, or does she need proof of intent to falsify?

  5. Likely effectiveness: Which option is most likely to actually prevent harm? The answer to this affects whether the stronger obligation (required, not merely permitted) kicks in.

Rights-Based Analysis

Multiple rights are in tension:

  • Patients' right to safe medication — a genuine safety interest
  • Priya's right not to be coerced — she was given a veiled threat
  • The company's legal rights — due process before sanctions
  • Employees' rights to a stable employment relationship — her own and her colleagues'

From a Kantian perspective: is the company treating patients as mere means — as revenue sources rather than as rational agents whose right to accurate safety information is fundamental?

The Courage Question

Aristotle defined moral courage as the mean between cowardice and recklessness. How do the four options map onto this spectrum?

  • Option 1 (do nothing) almost certainly falls toward cowardice — at minimum, it requires Priya to tell herself a story about uncertainty that she may not fully believe
  • Option 4 (go public immediately) might be reckless if internal and regulatory channels genuinely haven't been tried
  • The morally courageous path probably involves Options 2 and/or 3, with full documentation and legal advice before proceeding

Discussion Questions

  1. Priya's supervisor gave her a veiled warning, not a direct threat. How much does the implicit threat change her moral analysis? Does she now have a stronger obligation to report, or does the threat make non-disclosure more justifiable?

  2. Priya does not know whether any patient has been harmed. Does moral obligation require proof of harm, or is serious risk of harm sufficient? How does the severity of potential harm affect your answer?

  3. Federal whistleblower protection laws exist partly to make it less personally costly to report safety violations. Does the existence of legal protection change the moral calculus? (Hint: DeGeorge's framework was developed partly in the context of cases where there was no legal protection.)

  4. Suppose Priya submits the formal compliance report (Option 2) and hears nothing for three months. At what point, if any, does her obligation to escalate increase? What further information would you want before advising her to go to the FDA?

  5. What does Priya owe her colleagues who did not falsify the records but who would certainly be disrupted by an investigation? Does loyalty to them count as a morally relevant consideration, or is it a rationalization of inaction?

A Note on Resolution

There is no single "correct" answer to Priya's dilemma that all reasonable people applying the frameworks correctly will reach. The frameworks give us structure for the analysis, not an algorithm that produces answers.

What they do is make it harder to hide behind vagueness. After working through DeGeorge, Aristotle, and a rights analysis, Priya — and you — cannot simply say "it's complicated." You have to say which specific consideration you're weighing most heavily and why, and you have to be honest about whether that weighting reflects your actual values or your fear.

That's the philosophical work.